SG11201808306PA - Treatment of cancer with tg02 - Google Patents

Treatment of cancer with tg02

Info

Publication number
SG11201808306PA
SG11201808306PA SG11201808306PA SG11201808306PA SG11201808306PA SG 11201808306P A SG11201808306P A SG 11201808306PA SG 11201808306P A SG11201808306P A SG 11201808306PA SG 11201808306P A SG11201808306P A SG 11201808306PA SG 11201808306P A SG11201808306P A SG 11201808306PA
Authority
SG
Singapore
Prior art keywords
international
tgo2
mab
california
pct
Prior art date
Application number
SG11201808306PA
Inventor
Thomas M Estok
Eckard Weber
Tracy Parrott
Original Assignee
Tragara Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tragara Pharmaceuticals Inc filed Critical Tragara Pharmaceuticals Inc
Publication of SG11201808306PA publication Critical patent/SG11201808306PA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/529—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A61N2005/1092—Details
    • A61N2005/1098—Enhancing the effect of the particle by an injected agent or implanted device

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property -, Organization MD 110111101110101011111 010111110111011110111001111100101 1111110111 III International Bureau .. .... ..Yejd ..... ...1 (10) International Publication Number (43) International Publication Date WO 2017/165732 Al 28 September 2017 (28.09.2017) WIP0 I PCT (51) (21) (22) (25) Filing Language: (26) Publication Language: (30) (71) (72) Inventors: ESTOK, Thomas M.; 121 Formby, Williams- International Patent Classification: AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, A61K 31/535 (2006.01) C07D 498/06 (2006.01) BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, International Application Number: HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, PCT/US2017/023965 KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, International Filing Date: MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, 24 March 2017 (24.03.2017) NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, English TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, English ZA, ZM, ZW. Priority Data: (84) Designated States (unless otherwise indicated, for every 62/312,712 24 March 2016 (24.03.2016) US kind of regional protection available): ARIPO (BW, GH, 62/423,468 17 November 2016 (17.11.2016) US GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, Applicant: TRAGARA PHARMACEUTICALS, INC. TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, [US/US]; 3152 Lionshead Avenue, Carlsbad, California DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, 92010 (US). LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, burg, Virginia 23188 (US). WEBER, Eckard; 4040 Miller GW, KM, ML, MR, NE, SN, TD, TG). Street, San Diego, California 92103 (US). PARROTT, Published: Tracy; 212 Via Tavira, Encinitas, California 92024 (US). — with international search report (Art. 21(3)) Agents: ESMOND, Robert W. et al.; Sterne, Kessler, before the expiration of the time limit for amending the Goldstein & Fox P.L.L.C, 1100 New York Avenue, NW, claims and to be republished in the event of receipt of Washington, District of Columbia 20005 (US). amendments (Rule 48.2(h)) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, (74) (81) Title: TREATMENT OF 100 ?:- :•9 80 ._ > 60 6- .._, 40 20 0) a. (54) CANCER WITH TGO2 -4- IgG Control + Vehicle -0- TG02, 20 mglkg -lir- TG02, 40 mglkg -6- PD-1 mAb (1 Al2) -8- TG02, 20 mg/kg + PD-1 mAb - -a-TG02, 40 mg/kg + PD-1 mAb = 1-1 ei cr) IN kin 1-1 IN 1-1 (57) N agent, C and : The present disclosure e.g., TGO2 and an immune a COX-2 inhibitor. 0 20 40 60 80 100 Days after implantation Fig. 27 provides therapeutic methods of treating a cancer patient with TGO2 and a second therapeutic checkpoint inhibitor, TGO2 and a COX-2 inhibitor, or TGO2 and an immune checkpoint inhibitor
SG11201808306PA 2016-03-24 2017-03-24 Treatment of cancer with tg02 SG11201808306PA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662312712P 2016-03-24 2016-03-24
US201662423468P 2016-11-17 2016-11-17
PCT/US2017/023965 WO2017165732A1 (en) 2016-03-24 2017-03-24 Treatment of cancer with tg02

Publications (1)

Publication Number Publication Date
SG11201808306PA true SG11201808306PA (en) 2018-10-30

Family

ID=59899752

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201808306PA SG11201808306PA (en) 2016-03-24 2017-03-24 Treatment of cancer with tg02
SG10202005621WA SG10202005621WA (en) 2016-03-24 2017-03-24 Treatment of cancer with tg02

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG10202005621WA SG10202005621WA (en) 2016-03-24 2017-03-24 Treatment of cancer with tg02

Country Status (13)

Country Link
US (2) US11865116B2 (en)
EP (1) EP3432888B1 (en)
JP (2) JP7026299B2 (en)
KR (2) KR20230020549A (en)
CN (2) CN109195603B (en)
AU (1) AU2017238647B2 (en)
CA (1) CA3018875A1 (en)
ES (1) ES2941687T3 (en)
IL (1) IL261959B2 (en)
MX (2) MX2021012977A (en)
RU (1) RU2749025C2 (en)
SG (2) SG11201808306PA (en)
WO (1) WO2017165732A1 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230133934A (en) 2016-10-11 2023-09-19 아게누스 인코포레이티드 Anti-lag-3 antibodies and methods of use thereof
EP3664830A4 (en) 2017-08-07 2020-07-01 The Regents of the University of California Platform for generating safe cell therapeutics
JP7250764B2 (en) 2017-08-18 2023-04-03 コセラ バイオサイエンス， インコーポレイテッド Polymorphic forms of TG02
MX2021011301A (en) * 2019-03-18 2022-01-19 Univ Texas Tumor-selective combination therapy.
EP3958854A4 (en) 2019-04-22 2023-02-01 University of Pittsburgh - of The Commonwealth System of Higher Education Use of tg02 for treating gliomas in pediatric subjects
US20230287510A1 (en) * 2020-08-10 2023-09-14 The Broad Institute, Inc. Compositions, panels, and methods for characterizing chronic lymphocytic leukemia
WO2023092076A1 (en) * 2021-11-18 2023-05-25 Lantern Pharma Inc. Method for treating cancer with acylfulvene and radiation
CN114113051B (en) * 2021-12-16 2023-06-16 南京信息工程大学 Preparation method and application of PSMA electrochemiluminescence sensor
EP4197525A1 (en) 2021-12-20 2023-06-21 Scandion Oncology A/S Combination of drugs for the treatment of cancer
CN114480639B (en) * 2021-12-24 2022-09-30 中国医学科学院北京协和医院 Novel targets for diagnosis and treatment of pituitary adenomas
CN116510024A (en) * 2022-01-30 2023-08-01 上海复东生物医药有限责任公司 Composition, preparation method and application thereof
WO2023242235A1 (en) 2022-06-14 2023-12-21 Scandion Oncology A/S Abcg2 inhibitor and nae inhibitor for the treatment of cancer
CN115429793A (en) * 2022-08-15 2022-12-06 复旦大学附属中山医院 Application of compound in preparation of medicine for treating hepatocellular carcinoma

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR8108820A (en) 1980-09-24 1982-08-24 Cetus Corp DIAGNOSTIC PROCESS AND PROBE
US4582788A (en) 1982-01-22 1986-04-15 Cetus Corporation HLA typing method and cDNA probes used therein
EP0084796B1 (en) 1982-01-22 1990-05-02 Cetus Corporation Hla typing method and cdna probes used therein
US4683194A (en) 1984-05-29 1987-07-28 Cetus Corporation Method for detection of polymorphic restriction sites and nucleic acid sequences
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
CA1284931C (en) 1986-03-13 1991-06-18 Henry A. Erlich Process for detecting specific nucleotide variations and genetic polymorphisms present in nucleic acids
CA1338457C (en) 1986-08-22 1996-07-16 Henry A. Erlich Purified thermostable enzyme
US6605712B1 (en) 1990-12-20 2003-08-12 Arch Development Corporation Gene transcription and ionizing radiation: methods and compositions
WO2007058628A1 (en) * 2005-11-16 2007-05-24 S*Bio Pte Ltd Heteroalkyl linked pyrimidine derivatives
ES2632548T3 (en) * 2010-02-05 2017-09-14 Tragara Pharmaceuticals, Inc. Solid state forms of macrocyclic kinase inhibitors
US9636328B2 (en) * 2013-06-21 2017-05-02 Zenith Epigenetics Ltd. Substituted bicyclic compounds as bromodomain inhibitors
ES2827679T3 (en) 2013-08-20 2021-05-24 Merck Sharp & Dohme Cancer treatment with a combination of a PD-1 antagonist and dinaciclib
WO2015095840A1 (en) * 2013-12-20 2015-06-25 Biomed Valley Discoveries, Inc. Cancer treatments using combinations of cdk and erk inhibitors
EP3126525B1 (en) 2014-04-04 2020-02-19 Memorial Sloan-Kettering Cancer Center Method and kits for identifying of cdk9 inhibitors for the treatment of cancer
US10233170B2 (en) 2014-04-08 2019-03-19 Rigel Pharmaceuticals, Inc. 2,3-disubstituted pyridine compounds as TGF-beta inhibitors and methods of use
EP3925622A1 (en) 2014-09-13 2021-12-22 Novartis AG Combination therapies
JP7250764B2 (en) 2017-08-18 2023-04-03 コセラ バイオサイエンス， インコーポレイテッド Polymorphic forms of TG02

Also Published As

Publication number Publication date
RU2018137217A (en) 2020-04-24
EP3432888A4 (en) 2019-11-13
AU2017238647B2 (en) 2021-12-09
ES2941687T3 (en) 2023-05-24
IL261959B1 (en) 2023-04-01
SG10202005621WA (en) 2020-07-29
CN109195603B (en) 2022-11-08
AU2017238647A1 (en) 2018-10-25
JP2022050631A (en) 2022-03-30
RU2749025C2 (en) 2021-06-03
WO2017165732A1 (en) 2017-09-28
KR20190006948A (en) 2019-01-21
JP2019509354A (en) 2019-04-04
KR20230020549A (en) 2023-02-10
JP7026299B2 (en) 2022-02-28
CA3018875A1 (en) 2017-09-28
CN109195603A (en) 2019-01-11
IL261959A (en) 2018-10-31
US11865116B2 (en) 2024-01-09
MX2021012977A (en) 2022-10-03
US20200323862A1 (en) 2020-10-15
EP3432888A1 (en) 2019-01-30
US20240156824A1 (en) 2024-05-16
CN115969854A (en) 2023-04-18
RU2018137217A3 (en) 2020-05-29
EP3432888B1 (en) 2022-10-05
MX2022008868A (en) 2022-08-11
KR102491013B1 (en) 2023-01-31
IL261959B2 (en) 2023-08-01
JP7459149B2 (en) 2024-04-01

Similar Documents

Publication Publication Date Title
SG11201808306PA (en) Treatment of cancer with tg02
SG11201908391XA (en) Methods for modulating an immune response
SG11201804132UA (en) Eif4-a-inhibiting compounds and methods related thereto
SG11201809064QA (en) Chimeric neurotoxins
SG11201901364VA (en) Engineered target specific nucleases
SG11201804934PA (en) Novel Compounds
SG11201808990QA (en) Compositions for topical application of compounds
SG11201809344QA (en) Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde
SG11201901959YA (en) Modified stem cell memory t cells, methods of making and methods of using same
SG11201811491YA (en) Quinazoline and indole compounds to treat medical disorders
SG11201810280YA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201806863WA (en) Tetracyclic pyridone compounds as antivirals
SG11201903483VA (en) Compositions and methods for treating ezh2-mediated cancer
SG11201805570WA (en) Systems and methods for long term transdermal administration
SG11201909155VA (en) Ask1 inhibitor compounds and uses thereof
SG11201901996UA (en) Formulations of ( r)-2-amino-3-phenylpropyl carbamate
SG11201810525XA (en) Anti-gitr antibodies and uses thereof
SG11201907583TA (en) Methods for treating complement-mediated diseases and disorders
SG11201900554YA (en) Spiro-lactam nmda modulators and methods of using same
SG11201906436VA (en) Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same
SG11201811230RA (en) Compositions and methods for reducing ocular neovascularization
SG11201900551WA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201900546UA (en) Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof
SG11201900558RA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201900405XA (en) Compounds, compositions and methods for treating or preventing a sympton associated with gout or hyperuricemia